Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.385
+0.125 (5.53%)
Oct 28, 2026, 10:59 AM EDT - Market open
Ovid Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Ovid Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $6.00. The average 1-year stock price forecast is 151.57% higher than the current stock price, while the lowest is $4.00 (+67.71%) and the highest is $9.00 (+277.36%).
Price Target: $6.00 (+151.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ovid Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 10 | 13 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $5 | Buy | Initiates | $5 | +109.64% | Oct 15, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $6 | Buy | Initiates | $6 | +151.57% | Oct 9, 2026 |
| Wedbush | Wedbush | Buy Maintains $7 | Buy | Maintains | $7 | +193.50% | Oct 8, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $7 | Buy | Initiates | $7 | +193.50% | Oct 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $4 → $5 | Buy | Reiterates | $4 → $5 | +109.64% | Sep 11, 2026 |
Financial Forecast
Revenue This Year
791.62K
from 7.25M
Decreased by -89.08%
Revenue Next Year
325.62K
from 791.62K
Decreased by -58.87%
EPS This Year
-0.36
from -0.23
EPS Next Year
-0.37
from -0.36
EPS and Forward PE are based on non-GAAP adjusted numbers.